Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy
Provided By GlobeNewswire
Last update: May 8, 2025
Zervimesine treatment slowed the rate of GA lesion growth by 28.6% compared to placebo
Observed GA lesion area was reduced by 28.2% at 18 months compared to placebo
Read more at globenewswire.comNASDAQ:CGTX (6/2/2025, 11:50:42 AM)
0.27
+0.03 (+12.5%)
Find more stocks in the Stock Screener
